Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy

Roshan, Reyhaneh; Naderi, Shamsi; Behdani, Mahdi; Cohan, Reza Ahangari; Ghaderi, Hajarsadat; Shokrgozar, Mohammad Ali; Golkar, Majid; Kazemi‐Lomedasht, Fatemeh

doi:10.1016/j.molimm.2020.10.021

Cited by 24 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that repeated administration of Nb will not cause any humoral and cellular immune response. [19][20][21] but whether long-term repeated use of Nb drugs will cause its immunogenicity to the body remains to be studied. 22…”

Section: Structure and Physicochemical Features Of Nanobody Basic Structure Of Nanobodymentioning

confidence: 99%

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Sun¹,

Ding²,

Yang³

et al. 2021

IJN

View full text Add to dashboard Cite

The development of monoclonal antibody treatments for successful tumor-targeted therapies took several decades. However, the efficacy of antibody-based therapy is still confined and desperately needs further improvement. Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size (~15kDa), excellent solubility, superior stability, ease of manufacture, quick clearance from blood, and deep tissue penetration, which gain increasing acceptance as therapeutical tools and are considered also as building blocks for chimeric antigen receptors as well as for targeted drug delivery. Thus, one of the promising novel developments that may address the deficiency of monoclonal antibody-based therapies is the utilization of nanobodies. This article provides readers the significant factors that the structural and biochemical properties of nanobodies and the research progress on nanobodies in the fields of tumor treatment, as well as their application prospect.

show abstract

Section: Structure and Physicochemical Features Of Nanobody Basic Structure Of Nanobodymentioning

confidence: 99%

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Sun¹,

Ding²,

Yang³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…The use of antibodies against antigens with a potential prognostic and/or therapeutic use such as CD9, CD117, and CD326 (Foster et al, 2018; Roshan et al, 2021; Saito et al, 2006; Sakabe et al, 2017), also allowed us to quantitatively evaluate the expression of these targets. CD117 expression has been reported to correlate with high‐grade carcinoma and to be absent in carcinoid tumors, although we have shown expression in a proportion of patients with lung carcinoid tumor (Annunziata et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

“…CD117 expression has been reported to correlate with high‐grade carcinoma and to be absent in carcinoid tumors, although we have shown expression in a proportion of patients with lung carcinoid tumor (Annunziata et al, 2020). Although, no statistical differences in overall survival were found in advanced disease, expression of these antigens could be evaluated for novel antibody‐based therapies (Abrams et al, 2018; Roshan et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples

Quirós

Fernández

Fonseca-Mourelle

et al. 2022

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: Multidimensional flow cytometry (MFC) is routinely used for the diagnosis and follow-up of hematolymphoid neoplasms but its contribution to the identification of non-hematolymphoid malignant tumors is limited. Methods:The presence of non-hematolymphoid cells in clinical samples obtained via minimally invasive methods was ascertained by using a panel of monoclonal antibodies previously developed in our laboratory comprising a mixture of antibodies: CD9-PacB/CD45-OC515/CD57-FITC/CD56-PE/CD3-PerCP-Cy5.5/CD117-PE-Cy7/CD326-APC/CD81-APC-C750. Histopathological studies were performed using standard techniques.Results: 164 specimens of different origins were included. Malignancy was finally confirmed in 142 (86.5%), while 22 non neoplastic samples were identified. The most frequent diagnosis was small cell lung carcinoma (SCLC) (50%). High sensitivity (S = 98.6%) was reached combining MFC and conventional pathology. Individual markers differed according to the cellular origin of the neoplasm, with neuroendocrine tumors showing a unique immunophenotypic profile (CD56+ CD326+ CD117À/+ and variable tetraspanins expression). Principal component analysis efficiently distinguished SCLC from other tumor samples. In immune cell populations, differences between reactive and malignant biopsies were found in different cell compartments, especially in B cells and Plasma cells. Differences also emerged in the percentage of CD4+ CD8À T cells, CD4-CD8+ T cells and NK cells and these were dependent on the origin of the tumor cells.Conclusions: These results support the use of MFC as a rapid and valuable technique to detect non-hematolymphoid tumoral cells in clinical specimens, providing an initial orientation to complement hystopathological studies and allow a more precise diagnosis, especially in neuroendocrine neoplasms. The impact of different immune cell patterns warrants further research.

show abstract

“…The apparent affinity of selected Nbs was estimated by performing a saturated ELISA against immobilized BLG. , Generally, 10 μg/mL BLG was coated in microtiter plates. After blocking with 1% gelatin, Nbs with serial dilutions of 100,000, 10,000, 1000, 100, 10, 1, 0.1, 0.01, and 0.001 nM were added.…”

Section: Methodsmentioning

confidence: 99%

Exploration of Specific Nanobodies As Immunological Reagents to Detect Milk Allergen of β-Lactoglobulin without Interference of Hydrolytic Peptides

Wang

Nie

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

Milk proteins are widely used for food supplementation, despite the potential risk of food allergy, especially against βlactoglobulin (BLG), which makes BLG surveillance critical. Possible interaction of detecting antibodies with BLG-derived peptides will result in unprecise inspection. Thus, in this study, it was proposed to generate nanobodies (Nbs) and validate the immunological detection of intact BLG rather than hydrolytic peptides. Nbs were successfully retrieved and characterized with high stability and target specificity. A competitive enzyme-linked immunosorbent assay (cELISA) was developed with a linear range from 39 to 10,000 ng/mL and a detection limit (LOD) of 4.55 ng/mL, with a recovery of 86.30%−95.09% revealed by analysis of spiked samples. Meanwhile, a sandwich ELISA (sELISA) was established with Nb82 and BLG polyclonal antibody (pAb-BLG) providing a linear range from 29.7 to 1250 ng/mL and an LOD of 13.82 ng/mL with a recovery of 87.82%−103.97%. The interaction of selected Nbs with BLG-derived peptides was investigated by Nb structure modeling and BLG docking. No binding on hydrolytic peptides was revealed, confirming the precision of Nb-mediated immunoassays. In summary, this study successfully identified BLG-specific Nbs for immunoassay development and guaranteed the monitoring of intact BLG without interference of hydrolytic peptides, providing experimental evidence that our Nbs recognize intact food allergen.

show abstract

Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy

Cited by 24 publications

References 39 publications

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples

Exploration of Specific Nanobodies As Immunological Reagents to Detect Milk Allergen of β-Lactoglobulin without Interference of Hydrolytic Peptides

Contact Info

Product

Resources

About